Page 95 - TD-3-4

Tumor Discovery RNA-protein complexes deregulated in cancer

213. Qing Y, Dong L, Gao L, et al. R-2-hydroxyglutarate attenuates 224. Chanda S, Lepikhov K, Dahlem C, et al. Gene editing and
aerobic glycolysis in leukemia by targeting the FTO/m A/ small molecule inhibitors of the RNA binding protein
6
PFKP/LDHB axis. Mol Cell. 2021;81:922-939.e9. IGF2BP2/IMP2 show its potential as an anti-cancer drug
target. Front Biosci (Landmark Ed). 2024;29(1):41.
doi: 10.1016/j.molcel.2020.12.026
doi: 10.31083/j.fbl2901041
214. Ofir-Rosenfeld Y, Rausch O, McMahon J, et al. STC-15, an
oral small molecule inhibitor of the RNA methyltransferase 225. Huang Y, Su R, Sheng Y, et al., Small-Molecule Targeting of
METTL3, inhibits tumor growth through activation Oncogenic FTO Demethylase in Acute Myeloid Leukemia.
of anti-cancer immune responses and synergises with Cancer Cell. 2019, 35(4):677-691.e10.
immune checkpoint blockade. J Immunother Cancer. doi: 10.1016/j.ccell.2019.03.006
2022;10:A1-A1603.
226. Feng G, Wu Y, Hu Y, et al. Small molecule inhibitors
215. Guan Q, Lin H, Miao L, et al. Functions, mechanisms, and targeting m6A regulators. J Hematol Oncol. 2024;17(1):30.
therapeutic implications of METTL14 in human cancer.
J Hematol Oncol. 2022;15:13. doi: 10.1186/s13045-024-01546-5
doi: 10.1186/s13045-022-01231-5 227. Zálešák F, Nai F, Herok M, et al. Structure-based design
of a potent and selective YTHDC1 ligand. J Med Chem.
216. Albert L, Xu J, Wan R, Srinivasan V, Dou Y, Vázquez O. 2023;67:9516-9535.
Controlled inhibition of methyltransferases using
photoswitchable peptidomimetics: Toward an epigenetic doi: 10.1021/acs.jmedchem.4c00599
regulation of leukemia. Chem Sci. 2017;8:4612-4618. 228. Hollebecque A, Salvagni S, Plummer R, et al. Clinical
doi: 10.1039/c7sc00137a activity of CC-90011, an oral, potent, and reversible LSD1
inhibitor, in advanced malignancies. Cancer (Basel).
217. Lee JH, Choi N, Kim S, Jin MS, Shen H, Kim YC. Eltrombopag 2022;128(17):3185-3195.
as an allosteric inhibitor of the METTL3-14 complex
affecting the m6A methylation of RNA in acute myeloid doi: 10.1002/cncr.34366
leukemia cells. Pharmaceuticals (Basel). 2022;15(4):440. 229. Sahafnejad Z, Ramazi S, Allahverdi A. An update
doi: 10.3390/ph15040440 of epigenetic drugs for the treatment of cancers and
brain diseases: A comprehensive review. Genes (Basel).
218. Nai F, Flores Espinoza MP, Invernizzi A, et al. Small- 2023;14(4):873.
molecule inhibitors of the m7G-RNA writer METTL1. ACS
Bio Med Chem Au. 2023;4(2):100-110. doi: 10.3390/genes14040873
doi: 10.1021/acsbiomedchemau.3c00030 230. Li Y, Ren Y, Wang Y, et al. A compound AC1Q3QWB
selectively disrupts HOTAIR-mediated recruitment of PRC2
219. Li F, Li W. Readers of RNA modification in cancer and their and enhances the cancer therapy of DZNep. Theranostics.
anticancer inhibitors. Biomolecules. 2024;14(7):881.
2019;9:4608-4623.
doi: 10.3390/biom14070881
doi: 10.7150/thno.35188
220. Dahlem C, Abuhaliema A, Kessler SM, et al. First small- 231. Yang L, Tang L, Min Q, et al. Emerging role of RNA
molecule inhibitors targeting the RNA-binding protein modification and long noncoding RNA interaction in
IGF2BP2/IMP2 for cancer therapy. ACS Chem Biol. cancer. Cancer Gene Ther. 2024;31(6):816-830.
2022;17(2):361-375.
doi: 10.1038/s41417-024-00734-2
doi: 10.1021/acschembio.1c00833
232. Poole RM. Belinostat: First global approval. Drugs.
221. Wallis N, Oberman F, Shurrush K, et al. A small molecule 2014;74:1543-1554.
inhibitor of Igf2bp1 represses Kras and a prooncogenic
phenotype in cancer cells. RNA Biol. 2022;19(1):26-43. doi: 10.1007/s40265-014-0275-8
doi: 10.1080/15476286.2021.2010983 233. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R.
FDA approval summary: Vorinostat for treatment of
222. Feng P, Chen D, Wang X, et al. Inhibition of the m6A reader advanced primary cutaneous T-cell lymphoma. Oncologist.
IGF2BP2 as a strategy against T-cell acute lymphoblastic 2007;12:1247-1252.
leukemia. Leukemia. 2022;36(9):2180-2188.
doi: 10.1634/theoncologist.12-10-1247
doi: 10.1038/s41375-022-01651-9
234. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH.
223. Bao Y, Zhai J, Chen H, et al. Targeting m6A reader YTHDF1 Romidepsin (Istodax, NSC 630176, FR901228, FK228,
augments antitumour immunity and boosts anti-PD-1 depsipeptide): A natural product recently approved
efficacy in colorectal cancer. Gut. 2023;72:1497-1509.
for cutaneous T-cell lymphoma. J Antibiotics (Tokyo).
doi: 10.1136/gutjnl-2022-328845 2011;64:525-531.

Volume 3 Issue 4 (2024) 36 doi: 10.36922/td.4657